Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools
Log in
Sections
You are here: Home › Biostatistics and Clinical Data Management › Wing Keung (‘Michael’) Chiu, MS

Wing Keung (‘Michael’) Chiu, MS

Michael Chiu

Biostatistician

Biostatistics and Clinical Data Management Core Facility

919-843-1534

michael_chiu@med.unc.edu

 

Education

M.S. Applied Statistics. Michigan State University, 2007

B.S. Quantity Surveying. Hong Kong Polytechnic University, 2002

Publications

Brewer NT, Walko CM, Chiu WK, Dressler LG, Yuen A et al: Patient’s understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. American Society of Clinical Oncology Annual Meeting, 2011. Poster #6029.

Carey LA, Rugo H, Marcom PK, Mayer E, Esteva F, Ma C, Liu M, Storniolo AM, Rimawi M, Forero A, Wolff A, Ingle J, Ivanova A, Chiu WK, Ferraro M, Burrows E, et al: TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer. Journal of Clinical Oncology, 2011, In Press.

Chiu WK: Data Extraction from Oncore using SAS. SAS Global Forum 2010, #198-2010

Irvin WJ, Walko CM, Weck KE, Chiu WK, Ibrahim JG, et al: Multicenter study of genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism. Journal of Clinical Oncology 2010, In Press.

Irvin WJ, Orlowski RZ, Chiu WK, et al:  Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.  Accepted to Clinical Breast Cancer 3/2010, In Press.

Sanoff HK, Davies JM, Walko C, Irvin WJ, Buie L, Keller K, Ivanova A, Chiu WK, O’Neil BH, Stinchcombe TE, Dees EC:  A Phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.  Invest New Drugs.  2010 Apr 13 [Epub ahead of print].  PMID:20387090. PMCID:NIHM5203294.

Rosenman JG, Chen RC, Hoffman LG, Chiu WK, et al: Phase I study of concurrent weekly Docetaxel, Androgen Deprivation, and High-dose External Beam Radiation Therapy (RT) for High-risk Prostate Cancer. American Society of Radiation Oncology, Abstract #269, 2010

Xie L, Saynak M, Chiu WK, Bailey JE, et al: FDG-PET vs. Histologic Staging of the Mediastinum in Patients With Pathologic N0-1 Non-small Cell Lung Cancer (NSCLCa): What Should Be the Gold Standard?. Multidisciplinary Symposium in Thoracic Oncology, Abstract #106, 2010

Sanoff HK, Davies JM, Walko C, Buie L, Chiu WK, Ivanova A, O’Neil B, Stinchcombe TE, Keller K, Dees EC: Phase I trial of vinflunine and pemetrexed in refractory solid tumors.  Invest New Drugs.  2009 Oct 5. PMID: 19830387

Foster MC, Christensen R, Egan J, Chiu WK, et al: Prognostic impact of bone marrow CD138 immunohistochemistry (IHC) prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM). American Society of Clinical Oncology Annual Meeting, Abstract #8600, 2009

Getting Started

For new requests, a good first step may be to meet with one of us at our Walk-In Clinic.

Otherwise, please feel free to contact us by e-mailing Michael Chiu,  Allison M. Deal, , Dominic T. Moore, or .

For ongoing work, please use e-mail to contact the individual who is your main contact person for your Cancer Center Biostatistics and/or Clinical Data Management activity.

For urgent matters, please call Dominic at 919-966-8647.

Software

For access to free software for the design and analysis of clinical trials, click on the software links next to faculty and staff names.

Walk-In Clinic Hours

Now available on Tuesdays and Thursdays

12 noon to 1 p.m.

in the atrium on the first floor of the Lineberger building

What is a walk-in clinic? Learn more!

Welcome Dr. Anna Snavely

Born in Greensboro, Anna earned her undergraduate degree in mathematics with a concentration in statistics from Wake Forest University.  She completed her PhD in Biostatistics at Harvard University in 2012. Her dissertation work was motivated by cancer clinical trials and involved methods for analyzing clustered survival and multiple outcomes data.

While at Harvard, Anna was involved in many collaborative projects at Dana-Farber Cancer Institute. In particular, she worked with investigators at the Center for Community-Based Research, the Head and Neck Cancer Program, and the Lance Armstrong Foundation Adult Survivorship Program.

We are very pleased to have Anna with us! Please join us in welcoming her to our Cancer Center.